Clinical Scorecard: Elevating Ocular Surface Care

At a Glance

Key Highlights

• Ideal candidates include those with persistent epithelial defects and moderate to severe dry eye disease.
• Amniotic membrane therapy is effective for chemical injuries and ocular graft-versus-host disease.
• Proper coding and documentation are essential for reimbursement.
• Success rates are influenced by the ocular surface environment and underlying conditions.
• Early treatment in acute inflammatory conditions can improve outcomes.

Guideline-Based Recommendations

Diagnosis

• Use ICD-10 codes for persistent epithelial defects (H16.23x) and neurotrophic keratitis (H16.23x).
• Document underlying conditions and therapeutic intent.

Management

• Consider amniotic membrane therapy for patients with failed conservative treatment.
• Address underlying inflammation and promote epithelial healing.

Monitoring & Follow-up

• Assess the ocular surface for epithelial defects and corneal sensitivity.
• Monitor for signs of inflammation and treatment efficacy.

Risks

• Reduced success in cases of severe limbal stem cell deficiency.
• Potential complications from uncontrolled inflammation.

Patient & Prescribing Data

Patients with compromised immune systems, diabetes, and those undergoing ocular surgeries.

Amniotic membranes can aid in healing and reducing inflammation in various ocular surface disorders.

Clinical Best Practices

• Ensure proper documentation of clinical findings and treatment intent.
• Verify payer coverage and obtain prior authorizations when necessary.
• Utilize appropriate coding for procedures and diagnoses.

References

• Amniotic Membrane Therapy Guidelines